NVIDIA BioNeMo Core Path Traversal Leads to Code Execution (CVE-2026-24217)
The National Vulnerability Database has disclosed CVE-2026-24217, a high-severity path traversal vulnerability impacting NVIDIA BioNeMo Core for Linux. This flaw, rated 8.8 CVSS, allows an attacker to load a malicious file, potentially leading to arbitrary code execution, denial of service, information disclosure, and data tampering.
This isn’t just a theoretical bug. Path traversal vulnerabilities, especially with high CVSS scores, are routinely exploited in the wild. Attackers leverage these to escape intended directory restrictions, access sensitive files, or drop malicious payloads that facilitate further compromise. The fact that it can lead to code execution is a critical alarm bell.
For defenders, this means NVIDIA BioNeMo Core deployments on Linux are exposed. The attacker’s calculus is straightforward: find exposed instances, upload a crafted file, and gain a foothold. Given the potential for full system compromise, this needs immediate attention.
What This Means For You
- If your organization uses NVIDIA BioNeMo Core for Linux, you need to identify all deployments and monitor for patches related to CVE-2026-24217. Audit file upload mechanisms and enforce strict validation on file paths to prevent malicious file inclusions.
Indicators of Compromise
| ID | Type | Indicator |
|---|---|---|
| CVE-2026-24217 | Path Traversal | NVIDIA BioNeMo Core for Linux |
| CVE-2026-24217 | RCE | Loading a malicious file via path traversal in NVIDIA BioNeMo Core for Linux |
| CVE-2026-24217 | Information Disclosure | Loading a malicious file via path traversal in NVIDIA BioNeMo Core for Linux |
| CVE-2026-24217 | DoS | Loading a malicious file via path traversal in NVIDIA BioNeMo Core for Linux |
Source & Attribution
| Source Platform | NVD |
| Channel | National Vulnerability Database |
| Published | May 20, 2026 at 23:16 UTC |
This content was AI-rewritten and enriched by Shimi's Cyber World based on the original source. All intellectual property rights remain with the original author.
Believe this infringes your rights? Submit a takedown request.